A Comparative Analysis of the Sensitivity of Multidrug Resistant (MDR) and Non-MDR Cells to Different Anthracycline Derivatives

References

• Moscow J. A., Cowan K. H. Multidrug resistance. J. Natl. Cancer Inst. 1988; 80: 14–20
   PubMed Web of Science ®Google Scholar
• Kaye S. B. The multidrug resistance phenotype. J. Cancer 1988; 58: 691–694
   Web of Science ®Google Scholar
• Nooter K., Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer 1991; 63: 663–669
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesman M. Multiple drug resistance in human cancer. N. Eng. J. Med. 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Luk C. K., Tannock I. F. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J. Natl. Cancer Inst. 1989; 81: 55–59
   PubMed Web of Science ®Google Scholar
• Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979; 39: 2200–2203
   PubMed Web of Science ®Google Scholar
• Weistein R. S., Kuszak J. R., Kluskens L. F., Coon J. S. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Human Pathol. 1990; 21: 34–48
   PubMed Web of Science ®Google Scholar
• Hitchins R. N., Harman D. H., Davey R. A., Bell D. R. Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur. J. Cancer Clin. Oncol. 1988; 24: 449–454
   PubMedGoogle Scholar
• Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK-16. Cancer Res. 1988; 48: 1926–1929
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., O'Brien J. P., Casals D., Rittmann-Grauer L., Biedler J. L., Melamed M. T., Bertino J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989; 86: 695–698
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., Geromin A., Raspadori D., Fanin R., Savignano C., Giacca M., Pileri S., Mallardi F., Baccarani M. Expression of multidrug resistance gene (mdr-1) in normal human leukocytes. 1992, Submitted to Haematologica
   Google Scholar
• Pileri S. A., Sabattini E., Falini B., Tazzari P. L., Gherlinzoni F., Michieli M. G., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immuno-histochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathol. 1991; 19: 131–140
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Geromin A., Michelutti A., Fanin R., Raspadori D., Russo D., Visani G., Dinota A., Pileri S., Tsuruo T., Grandi M., Baccarani M., Tura S. Overexpression of multidrug resistance-associated P170-glycoprotein in acute non-lymphocytic leukemia. Eur. J. Haematol. 1992; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Michieli M., Raspadori D., Damiani D., Geromin A., Gallizia C., Michelutti A., Fanin R., Fasola G., Russo D., Tazzari P., Pileri S., Mallardi F., Baccarani M. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Brit. J. Haematol. 1991; 77: 460–465
   PubMed Web of Science ®Google Scholar
• Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieib A., Bennet J., Gottesman M., Pastan I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Brit. J. Haematol. 1990; 75: 340–345
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Rybski J. A., Scheper R. J., Richter L., Kailey J., Broxterman H. J., Pinedo H. M., Salmon S. E. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747–752
   PubMed Web of Science ®Google Scholar
• Speth P. A. J., Minderman H., Haanen C. Idarubicin v Daunorubicin: preclinical and clinical pharmaco-kinetic studies. Semin. Oncol. 1989; 16: 2–9
   PubMed Web of Science ®Google Scholar
• Schott B., Vrignaud P., Ries C., Robert J., Londos-Gagliardi D. Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin. Br. J. Cancer 1990; 61: 543–547
   PubMed Web of Science ®Google Scholar
• Barbieri B., Giuliani F. C., Bordoni T., Casazza A. M., Geroni C., Bellini O., Suarato A., Gioia B., Penco S., Arcamone F. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Cancer Res. 1987; 47: 4001–4006
   PubMed Web of Science ®Google Scholar
• Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. N. Eng. J. Med. 1981; 305: 139–153
   PubMed Web of Science ®Google Scholar
• Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976; 36: 467–475
   PubMed Web of Science ®Google Scholar
• Grandi M., Geroni C., Giuliani F. C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br. J. Cancer 1986; 54: 515–518
   PubMed Web of Science ®Google Scholar
• Foley G. E., Lazarus H., Farber S., Uzman B. G., Boone B. A., McCarthy R. E. Continuous culture of human lymphoblasts from peripheral blood of child with acute leukemia. Cancer 1965; 18: 522–529
   PubMed Web of Science ®Google Scholar
• Beck W. T., Mueller T. J., Tanzer L. R. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979; 39: 2070–2076
   PubMed Web of Science ®Google Scholar
• Ballinari D., Radice P., Grandi M., Sozzi G., Pezzoni G., Mondini P., Pierotti M. A., Giuliani F. C. MDR amplification and karyotypic analysis of anthracycline-resistant human tumor cell lines. Cancer Communic. 1988; 3: 69–74
   Google Scholar
• Shen D. W., Fojo A., Chin L. E., Roninson I. B., Richert N., Pastan I., Gottesman M. M. Human multidrug-resistant cell lines: increased mdr-1 expression can precede gene amplification. Science 1986; 232: 643–645
   PubMed Web of Science ®Google Scholar
• Lozzio C. B., Lozzio B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321–334
   PubMed Web of Science ®Google Scholar
• Lasky S. R., Bell W., Huhn R. D., Posner M. R., Wiemann M., Calabresi P., Eil C. Effects of lα, 25-Dihydroxyvitamin D3 on the human chronic myelogenous leukemia cell line RWLeu-4. Cancer Res. 1990; 50: 3087–3094
   PubMed Web of Science ®Google Scholar
• Pulfertaft R. J. Cytology of Burkitt's tumor (african lymphoma). Lancet 1964; 1: 238–242
   PubMed Web of Science ®Google Scholar
• Collins S. J., Gallo R. C., Gallagher R. E. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 1977; 270: 347–349
   PubMed Web of Science ®Google Scholar
• Brahic M., Haase A. T. Detection of viral sequences of low reiteration frequency by in situ hybridization. Proc. Natl. Acad. Sci. USA 1978; 75: 6125–6129
   PubMed Web of Science ®Google Scholar
• Chen C., Clark D., Ueda K., Pastan I., Gottesman M., Roninson I. B. Genomic organization of the human multidrug resistance (mdr-1) gene and origin of P-glycopro-teins. J. Biol. Chem. 1990; 265: 506–514
   PubMed Web of Science ®Google Scholar
• Samoszuk M., Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75: 13–16
   PubMed Web of Science ®Google Scholar
• Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1986; 83: 7785–7789
   PubMed Web of Science ®Google Scholar
• Schmid I., Schmid P., Giorgi J. V. Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry 1988; 9: 533–538
   PubMedGoogle Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Finlay G. J., Wilson W. R., Bagulei B. C. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukemia cell lines. Int. J. Cancer Clin. Oncol. 1986; 22: 655–662
   PubMedGoogle Scholar
• Salmon S. E., Liu R. M., Casazza A. M. Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother. Pharmacol. 1981; 6: 103–110
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Fox N. E., Wright K. A., Workman P., Broadhurst M. J., Martin J. A., Bleehen N. M. The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br. J. Cancer 1986; 53: 585–594
   PubMed Web of Science ®Google Scholar
• Kaye S., Merry S. Tumor cell resistance to anthracyclines-A review. Cancer Chemother. Pharmacol. 1985; 14: 96–103
   PubMed Web of Science ®Google Scholar
• Hill B. T., Dennis L. Y., Li X. T., Whelan R. D. H. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother. Pharmacol. 1985; 14: 194–201
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M., Clarkson B. Clinical implications of idarubicin pharmacology. Haematologica 1991; 76(suppl. 4)8
   PubMedGoogle Scholar
• Speth P. A. J. Cellular pharmacokinetics and pharmacodynamics of anthracyclines in man. SSN, Nijmegen, Druk 1986
   Google Scholar
• Luk C. K., Tannock I. F. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J. Natl. Cancer Inst. 1989; 81: 55–59
   PubMed Web of Science ®Google Scholar
• Gerlach J. H., Endicott J. A., Juranka P. F., Henderson G., Sarangi F., Deuchars K. L., Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485–489
   PubMed Web of Science ®Google Scholar
• Cornwell M. M., Safa A. R., Felstead R. L., Gottesman M., Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labelling. Proc. Natl. Acad. Sci. USA 1986; 83: 3847–3850
   PubMed Web of Science ®Google Scholar
• Cornwell M. M., Pastan I., Gottesman M. M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 1987; 262: 2166–2170
   PubMed Web of Science ®Google Scholar
• Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979; 39: 2200–2203
   PubMed Web of Science ®Google Scholar
• Krishan A., Ganapathi R. Laser flow cytometry studies on the intracellular fluorescence of anthracyclines. Cancer Res. 1980; 40: 3895–3900
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Iida H., Tsukagoslin S., Sakwai Y. Overcoming of vincristine resistance in P388 leukemia through enhanced cytotoxicity by verapamil. Cancer Res. 1981; 41: 1967–1972
   PubMed Web of Science ®Google Scholar
• Yusa K., Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites, and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989; 49: 5002–5006
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Fox N. E., White D. J. G. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line. Brit. J. Cancer 1987; 56: 55–57
   PubMed Web of Science ®Google Scholar
• Gosland M. P., Lum B. L., Sikie B. I. Reversal by cefoperazone of resistance to etoposide, doxorubicin and vinblastine in multi-drug resistant human sarcoma cells. Cancer Res. 1989; 49: 6901–6905
   PubMed Web of Science ®Google Scholar
• De Gregorio M. W., Ford J. M., Benz C. C., Wiebe V. J. Toremifene: pharmacologic and pharmacokinetics basis of reversing multidrug resistance. J. Clin. Oncol. 1989; 7: 1359–1364
   PubMed Web of Science ®Google Scholar
• Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991; 51: 4226–4233
   PubMed Web of Science ®Google Scholar
• Berman E., Adams M., Duigou-Osterndorf R., Godfrey L., Clarkson B., Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818–825
   PubMed Web of Science ®Google Scholar
• Krishan A., Sridhar K. S., Davila E., Vogel C., Sternheim W. Patterns of anthracycline retention modulation in human tumor cells. Cytometry 1987; 8: 306–314
   PubMedGoogle Scholar
• Holmes J. A. Multidrug resistance in leukaemia. Leuk. and Lymph. 1990; 1: 163–168
   PubMedGoogle Scholar
• Michieli M., Giacca M., Fanin R., Damiani D., Geromin A., Baccarani M. mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment. Brit. J. Haematol. 1991; 78: 290–291
   PubMed Web of Science ®Google Scholar
• Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 1991; 83: 111–116
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Nooter K., Burghouts J., Th M., Herweijer H., Adriaansen H. J., van Dongen J. J. M. High expression of the mdr-3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496–1500
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdr-1 and mdr-3 mutlidrug-resisitance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl. Cancer Inst. 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Wiernik P. H., Banks P. H. L., Case D. C., Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R. E., Weitberg A. B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Mandelli F., Petti M. C., Ardia A., Di Pietro N., Di Raimondo F., Ganzina F., Falconi E., Geraci E., Ladogana S., Latagliata R., Malleo C., Nobile F., Petti N., Rotoli B., Specchia G., Tabilio A., Resegotti L. A randomized clinical trial comparing idarubicin and cytarbine to daunorubicin and cytarabine in the treatment of acute nonlymphoid leukemia. Eur. J. Cancer 1991; 27: 750–756
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Velez-Garcia E., Omura G., Raney M. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Semin. Oncol. 1989; 16: 21–24
   PubMed Web of Science ®Google Scholar